Spektrum der Augenheilkunde

, Volume 19, Issue 2, pp 68–71 | Cite as


  • U. Schmidt-Erfurth
  • G. Langmann
  • G. Kieselbach
  • U. Schönherr
  • A. Wedrich
  • S. Binder


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Sallmann L (1950) Experimental study on the vitreous; II. Experiments on disappearance of red blood cells from the vitreous effects of hyaluronidase; effect of short bouts of artificial fever and changes in the basic metabolic rate. Arch Ophthalmol 43(4): 638–52Google Scholar
  2. 2.
    Henry K et al (1987) Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. Am J Ophthalmol 103(1): 17–23PubMedGoogle Scholar
  3. 3.
    Blankenship GW (1989) Evaluation of a single intravitreal injection of 5-fluorouracil in vitrectomy cases. Graefes Arch Clin Exp Ophthalmol 227(6): 565–8PubMedCrossRefGoogle Scholar
  4. 4.
    Hassan AS et al (1999) Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement. Ophthalmology 106(10): 1900–6; discussion 1906–7PubMedCrossRefGoogle Scholar
  5. 5.
    Jonas JB, Sofker A (2001) Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 132(3): 425–7PubMedCrossRefGoogle Scholar
  6. 6.
    Benhamou N et al (2003) Intravitreal triamcinolone for refractory pseudophakic macular edema. Am J Ophthalmol 135(2): 246–9PubMedCrossRefGoogle Scholar
  7. 7.
    Bynoe LA, Weiss JN (2003) Retinal endovascular surgery and intravitreal triamcinolone acetonide for central vein occlusion in young adults. Am J Ophthalmol 135(3): 382–4PubMedCrossRefGoogle Scholar
  8. 8.
    Antcliff RJ et al (2001) Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 108(4): 765–72PubMedCrossRefGoogle Scholar
  9. 9.
    Penfold PL et al (1995) Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust N Z J Ophthalmol 23(4): 293–8CrossRefGoogle Scholar
  10. 10.
    Krepier K, Wagner J, Sacu S, Wedrich A (2004) The effect of intravitreal triamcinolone on diabetic macular edema. Graefes Arch Clin Exp Ophthalmol, EpubGoogle Scholar
  11. 11.
    Isenberg SJ et al (1985) Chemical preparation of the eye in ophthalmic surgery. IV. Comparison of povidone-iodine on the conjunctiva with a prophylactic antibiotic. Arch Ophthalmol 103(9): 1340–2PubMedGoogle Scholar
  12. 12.
    Mather R et al (2002) Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol 133(4): 463–6PubMedCrossRefGoogle Scholar
  13. 13.
    Moshfeghi DM et al (2003) Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 136(5): 791–6PubMedCrossRefGoogle Scholar
  14. 14.
    Kupperman BD et al (2004) Ovine hyaluronidase (Vitrase, an investigational drug) reduces vitreous hemorrhage density (RVHD) and improves est corrected visual acuity (BCVA): Integrated results from 2 phase III studies. Presented at: Annual Meeting of the Association for Research in Vision and Ophthalmology, April 25–29; Ft. Lauderdale, FloridaGoogle Scholar
  15. 15.
    Danis RP et al (2000) Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 20(3): 244–50PubMedCrossRefGoogle Scholar
  16. 16.
    Gragoudas ES et al (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351(27): 2805–16PubMedCrossRefGoogle Scholar
  17. 17.
    Jager RD et al (2004) Risks of intravitreous injection: a comprehensive review. Retina 24(5): 676–98PubMedCrossRefGoogle Scholar
  18. 18.
    Eifrig CW et al (2002) Acute-onset postoperative endophthalmitis: review of incidence and visual outcomes (1995–2001). Ophthalmic Surg Lasers 33(5): 373–8PubMedGoogle Scholar
  19. 19.
    Sandvig KU, Dannevig L (2003) Postoperative endophthalmitis: establishment and results of a national registry. J Cataract Refract Surg 29(7): 1273–80PubMedCrossRefGoogle Scholar
  20. 20.
    Nelson ML et al (2003) Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 23(5): 686–91PubMedCrossRefGoogle Scholar
  21. 21.
    Endophthalmitis Vitrectomy Study Group (1995) Results of the endophthalmitis vitrectomy study group. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol 113: 1479–1496Google Scholar
  22. 22.
    Sutter FKP, Gillies MC (2003) Interim (3 months) analysis of the safety of intravitreal triamcinolone for diabetic macular edema that persists after laser treatment. Results from a randomized clinical trial: TDMO. Invest Ophthalmol Vis Sci 44: 454Google Scholar
  23. 23.
    Benz MS et al (2003) Endophthalmitis caused by Mycobacterium chelonae abscessus after intravitreal injection of triamcinolone. Arch Ophthalmol 121(2): 271–3PubMedGoogle Scholar
  24. 24.
    Müller M et al (2003) Komplikationen nach intravitrealer Triamcinolon-Acetonid-Injektion. Ophthalmologe 100: 192, Abstract.CrossRefGoogle Scholar
  25. 25.
    Nelson ML, Martidis A (2003) Managing cystoid macular edema after cataract surgery. Curr Opin Ophthalmol 14(1): 39–43PubMedCrossRefGoogle Scholar
  26. 26.
    Modarres M, Parvaresh MM, Peyman GA (1998) Accidental subretinal injection of triamcinolone acetonide. Ophthalmic Surg Lasers 29(11): 935–8PubMedGoogle Scholar
  27. 27.
    Bakri SJ, Beer PM (2003) The effect of intravitreal triamcinolone acetonide on intraocular pressure. Ophthalmic Surg Lasers Imaging 34(5): 386–90PubMedGoogle Scholar
  28. 28.
    Wingate RJ, Beaumont PE (1999) Intravitreal triamcinolone and elevated intraocular pressure. Aust N Z J Ophthalmol 27(6): 431–2PubMedCrossRefGoogle Scholar
  29. 29.
    Gillies MC et al (2005) Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology 112(1): 139–43PubMedCrossRefGoogle Scholar
  30. 30.
    Food and Drug Administration Department of Health & Human Services (2004) New drug application (NDA) 21–756. Macugen (pegaptanib sodium injection) application informationGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • U. Schmidt-Erfurth
  • G. Langmann
  • G. Kieselbach
  • U. Schönherr
  • A. Wedrich
  • S. Binder

There are no affiliations available

Personalised recommendations